Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha ® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke
VESALIUS-CV is the Latest Study in Amgen's PROFICIO Clinical Program Investigating the Impact of Repatha on CVD in Multiple Patient Populations Phase 3 Study Will Enroll High-Risk Patients who Have Significant Atherosclerotic Disease or Diabetes and are at High Risk for a First Cardiovascular Event THOUSAND OAKS, Calif., March 15, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced plans to conduct VESALIUS-CV, a multinational clinical outcomes study for Repatha® (evolocumab) which will involve at least 13,000 patients worldwide at high risk of experiencing a first cardiovascular (CV) event, despite optimiz...
Source: Amgen News Release - March 15, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen and Jay Leno Partner to Sound the Alarm on High Cholesterol and its Link to Heart Attack and Stroke in Patients Most at Risk
If You've had a Heart Attack or Stroke, Your Risk of Having Another Cardiovascular Event is Nearly One in Three(1) Cholesterol 911 Urges These High-Risk Patients to See the Emergency in High Cholesterol and Talk to Their Doctor About Ways to Reduce the Risk of Another Heart Attack and Stroke THOUSAND OAKS, Calif., March 12, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today launched Cholesterol 911, a national initiative urging high-risk cardiovascular disease patients to reduce their risk of another heart attack or stroke by addressing their continued high LDL-C, or "bad" cholesterol. Comedian and televi...
Source: Amgen News Release - March 12, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces 2019 Second Quarter Dividend
THOUSAND OAKS, Calif., March 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the second quarter of 2019. The dividend will be paid on June 7, 2019, to all stockholders of record as of the close of business on May 17, 2019. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understan...
Source: Amgen News Release - March 7, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present At The Cowen and Company 39th Annual Healthcare Conference
THOUSAND OAKS, Calif., March 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 39th Annual Healthcare Conference at 9:20 a.m. ET on Tuesday, March 12, 2019, in Boston. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event. About Amgen Amgen is committed to unlocking the potential of biology for patient...
Source: Amgen News Release - March 7, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

New Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha ® (evolocumab) Across Multiple Patient Populations
Results From TAUSSIG Study Reinforce Repatha's Safety and Efficacy in Patients With Genetic Risk of High Cholesterol Several Real-World Evidence Studies Highlight Continued Unmet Need and Suboptimal Treatment of High-Risk Cardiovascular Disease Patients THOUSAND OAKS, Calif., March 6, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of nine cardiovascular scientific research abstracts, including safety and efficacy results from the largest and longest open label study of homozygous familial hypercholesterolemia (HoFH) patients (TAUSSIG),1  as well as a sub-analysis from the Repatha...
Source: Amgen News Release - March 6, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Highlights Progress Of Innovative Early Oncology Pipeline With New Data At AACR 2019
First Preclinical Data to be Presented on AMG 510, a First-in-Class KRASG12C Inhibitor for Solid Tumors New Preclinical Data Evaluating AMG 757 to Highlight Half-Life Extended BiTE® Immunotherapy AMG 176 Preclinical Data Showcase Potential in Combination With Standard of Care Treatments for Acute Myeloid Leukemia THOUSAND OAKS, Calif., Feb. 28, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its early-stage oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, March 29 – April 3, 2019. "At Amgen, we ar...
Source: Amgen News Release - February 28, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Jury Upholds Amgen's Patents On Repatha ® (evolocumab)
THOUSAND OAKS, Calif., Feb. 25, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These patents describe and claim antibodies, like Amgen's innovative Repatha® (evolocumab) product, that bind to a specific region on PCSK9 and reduce LDL-C levels in the body. This verdict follows a previous trial in March 2016 where Sanofi and Regeneron admitted infringement of Amgen's patents and where a prior jury also upheld the validity of Amgen's patents. The prior jury decision was partiall...
Source: Amgen News Release - February 25, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Feb. 21, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment. Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF). METEORIC-HF is designed to evaluate the effect of ...
Source: Amgen News Release - February 21, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Reports Fourth Quarter And Full Year 2018 Financial Results
THOUSAND OAKS, Calif., Jan. 29, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2018 in comparison to comparable periods in 2017. Key results include: For the fourth quarter, total revenues increased 7 percent to $6.2 billion. Product sales grew 8 percent globally. New and recently launched products including Repatha® (evolocumab), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab) showed double-digit growth. For the full year, total revenues increased 4 percent to $23.7 billion, with 3 percent product s...
Source: Amgen News Release - January 29, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Webcast of 2018 Fourth Quarter and Full Year Financial Results
THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2018 financial results on Tuesday, Jan. 29, 2019, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news m...
Source: Amgen News Release - January 24, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Receives NMPA Approval For Repatha ® (evolocumab) In China To Reduce The Risk Of Cardiovascular Events
Innovative LDL-C Lowering Treatment has now Been Approved for High-Risk Patients in China With Cardiovascular Disease THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the National Medical Products Administration (NMPA) has approved a new indication for Repatha® (evolocumab) as the first PCSK9 inhibitor in China for adults with established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of myocardial infarction, stroke and coronary revascularization. Low-density lipoprotein cholesterol (LDL-C) is one of the key modifiable risk factors for the deve...
Source: Amgen News Release - January 24, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab
Study Evaluated Pharmacokinetics, Efficacy and Safety of ABP 798 Compared to Rituximab in Patients With Moderate-to-Severe Rheumatoid Arthritis THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a Phase 1/ Phase 3 study evaluating the pharmacokinetics, efficacy and safety of biosimilar candidate ABP 798, a biosimilar candidate to RITUXAN® (rituximab), compared to rituximab in patients with moderate-to-severe rheumatoid arthritis. The results demonstrate that the study met its primary endpoint of pharmacokine...
Source: Amgen News Release - January 24, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

European Commission Approves BLINCYTO ® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
BLINCYTO is the First and Only Therapy for Minimal Residual Disease Approved in the European Union Approval Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia THOUSAND OAKS, Calif., Jan. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO® (blinatumomab) monotherapy to include adult patients with Philadelphia chromosome negative (Ph-) CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remissi...
Source: Amgen News Release - January 22, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY ™ (romosozumab)
Potential New Treatment Option for the Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture THOUSAND OAKS, Calif. and BRUSSELS, Jan. 16, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval of EVENITY™* (romosozumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture after reviewing safety and efficacy data from the pivotal Phase 3 studies. Eighteen of 19 members vote...
Source: Amgen News Release - January 16, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

EVENITY ™ (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture
EVENITY Approved to Reduce the Risk of Fractures and Increase Bone Mineral Density in Men and Postmenopausal Women With Osteoporosis at High Risk of Fracture EVENITY in Japan is Being Co-Developed Through a Strategic Alliance With Amgen Astellas BioPharma THOUSAND OAKS, Calif. and BRUSSELS, Belgium, Jan. 8, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the Japanese Ministry of Health, Labor and Welfare has granted a marketing authorization for EVENITY™ (romosozumab) for the treatment of osteoporosis in patients at high risk of fracture.1 Amgen and UCB are c...
Source: Amgen News Release - January 8, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Makes All Repatha ® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price
The Repatha Pre-Filled Syringe and Repatha Pushtronex® System are Now Available at a Reduced List Price of $5,850 Majority of Repatha Medicare Patients Now Have Access at a Significantly Lower Out-of-Pocket Cost THOUSAND OAKS, Calif., Jan. 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that as part of the Company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, all Repatha® (evolocumab) device options, including the Pre-Filled Syringe and Pushtronex® (on-body infusor with pre...
Source: Amgen News Release - January 7, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present At The 37th Annual J.P. Morgan Healthcare Conference
THOUSAND OAKS, Calif., Jan. 3, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 37th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PT on Tuesday, Jan. 8, 2019, in San Francisco. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 9...
Source: Amgen News Release - January 3, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Submits Supplemental Biologics License Application For Nplate ® (romiplostim)
Application Seeks to Include Adult Patients who Have had Immune Thrombocytopenia for 12 Months or Less THOUSAND OAKS, Calif., Dec. 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Nplate® (romiplostim) to include the treatment of adult patients with immune thrombocytopenia (ITP) who have had ITP for 12 months or less and an insufficient response to corticosteroids, immunoglobulins or splenectomy. "Patients living with ITP need more flexibility in their treatment options, and we...
Source: Amgen News Release - December 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Molecular Partners Announce Strategic Collaboration In Immuno-Oncology
Parties Will Jointly Develop MP0310, a Pre-clinical FAP x 4-1BB Multi-Specific DARPin® Molecule, in Combination with Amgen's Oncology Assets, Including BiTE® Molecules Molecular Partners Retains Rights to Develop MP0310 in Combination With its Pipeline Products THOUSAND OAKS, Calif. and ZURICH-SCHLIEREN, Switzerland, Dec. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics, today announced a collaboration and license agreement for the clinical development and commercialization of MP0310 (FAP x...
Source: Amgen News Release - December 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Engages Cambridge Biotech Community To Select 2018 LabCentral Golden Ticket Winners
Amgen Golden Tickets Provide Startup Companies With Free Lab Space to Further Advance Innovative Science and Technology CAMBRIDGE, Mass., Dec. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and LabCentral today announced that Kernal Biologics and PanTher Therapeutics have each won the Amgen Golden Ticket at LabCentral. The two Golden Ticket winners were chosen by an Amgen internal committee and live audience members at a "Quick Pitch" event hosted by Amgen at its Cambridge, Mass. facility on Dec. 11, 2018. Six finalists pitched their business plans to attendees where the audience members' votes served as input...
Source: Amgen News Release - December 18, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
Filing for ABP 710, a Biosimilar Candidate to Infliximab, Supported by Phase 3 Study in Patients With Moderate-to-Severe Rheumatoid Arthritis THOUSAND OAKS, Calif., Dec. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to REMICADE® (infliximab). "At Amgen, we have spent nearly four decades developing, manufacturing and producing transformative medicines. We're leveraging our deep expertise and heritage in biologics to produce a portfolio of biosimilars t...
Source: Amgen News Release - December 17, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves Nplate ® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia
Application Granted Priority Review Designation Approval Based on Results That Demonstrated Nplate Successfully Increased and Sustained Platelet Counts in Children Affected by Rare Blood Disorder THOUSAND OAKS, Calif., Dec. 14, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) for the treatment of pediatric patients one year of age and older with immune thrombocytopenia (ITP) for at least six months who have had an insufficient response to corticosteroids, immunoglob...
Source: Amgen News Release - December 14, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Direct Relief Partner To Aid Cancer Patients In 18 Developing Countries
Amgen Donates $93 Million Worth of Cancer Medicines THOUSAND OAKS, Calif. and SANTA BARBARA, Calif., Dec. 13, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Direct Relief today announced a joint initiative in which Direct Relief will distribute $93 million worth of Amgen donated cancer treatments and supportive care medicines. This donation will provide cancer patients in 18 developing countries access to Neulasta® (pegfilgrastim), NEUPOGEN® (filgrastim) and Vectibix® (panitumumab). Patients will access the donated medicines through Direct Relief-partner hospitals and clinics in the following countries: Ar...
Source: Amgen News Release - December 13, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

deCODE Genetics, An Amgen Subsidiary, And SomaLogic Announce Collaboration To Perform Large-Scale Protein Analysis Of Up To 40,000 Human Samples
Largest-ever Protein Measurement Study Enhances deCODE's Efforts in Basic Research, Drug Discovery and Novel Protein-based DiagnosticsREYKJAVIK, Iceland and BOULDER, Colo., Dec. 13, 2018 /PRNewswire/ -- deCODE genetics, an Amgen subsidiary, and SomaLogic, Inc. today announced a collaboration that brings together SomaLogic's expertise in human proteins with deCODE's expertise in human genetics. The collaboration combines deCODE's rich data sets with SomaLogic's leading protein measurement capabilities to enhance the understanding of how human disease and health are mediated through proteins to influence health outcomes.&quo...
Source: Amgen News Release - December 13, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Magellan Rx Management Collaborate To Improve Patient Care For Chronic, Difficult-To-Treat Conditions
First Amgen-Pharmacy Benefit Manager Value-Based Agreement to Deliver Advanced Solutions for Osteoporosis and Migraine THOUSAND OAKS, Calif., Dec. 11, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced a novel multi-year collaboration with Magellan Rx Management, the pharmacy benefit management division of Magellan Health, that will leverage each company's capabilities and resources to identify clinical gaps for some of the healthcare system's most difficult-to-treat diseases. Based on Amgen and Magellan's extensive expertise in complex areas of health and specialty populations, the initial projects will fo...
Source: Amgen News Release - December 11, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Lazarex Cancer Foundation Team Up To Allow More Diversity In Clinical Trials
Amgen Contributes $2 Million to Groundbreaking Program Providing Cancer Patients of all Backgrounds Access to U.S. Clinical Trials THOUSAND OAKS, Calif. and SAN FRANCISCO, Dec. 10, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and the Lazarex Cancer Foundation, a non-profit organization focused on improving patient access to cancer clinical trials, today announced that they have teamed up to support more equitable access to clinical trials for cancer patients in the U.S. Through a corporate donation, Amgen has contributed $2 million to Lazarex's IMPACT (IMproving Patient Access to Cancer Clinical Trials) program, whic...
Source: Amgen News Release - December 10, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend
THOUSAND OAKS, Calif., Dec. 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the first quarter of 2019. The dividend will be paid on March 8, 2019, to all stockholders of record as of the close of business on Feb. 15, 2019. This represents a 10 percent increase from that paid in each of the previous four quarters. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins ...
Source: Amgen News Release - December 7, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE ® Immunotherapies AMG 420 And AMG 330 At ASH 2018
Phase 1 Results of Amgen's BiTE® Platform in Heavily Pre-Treated Patients With Multiple Myeloma and Acute Myeloid Leukemia FDA Grants Fast Track Designation for AMG 420 THOUSAND OAKS, Calif., Dec. 3, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the first clinical results from studies evaluating investigational novel bispecific T cell engager (BiTE®) immunotherapies AMG 420 and AMG 330. In two separate Phase 1 dose escalation studies, AMG 420, which targets B-cell maturation antigen (BCMA), and AMG 330, which targets CD33, provided early evidence of tolerability and anti-tumor activity in pat...
Source: Amgen News Release - December 4, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present At The Citi Global Healthcare Conference
THOUSAND OAKS, Calif., Dec. 3, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Citi Global Healthcare Conference at 12:35 p.m. ET on Thursday, Dec. 6, 2018, in New York City. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event. About Amgen Amgen is committed to unlocking the potential of biology for patients s...
Source: Amgen News Release - December 3, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY ™ (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
THOUSAND OAKS, Calif. and BRUSSELS, Nov. 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) will review data supporting the Biologics License Application (BLA) for EVENITYTM (romosozumab) for the treatment of osteoporosis in postmenopausal women at high risk for fracture at a meeting on Jan. 16, 2019. "After a fracture, postmenopausal women with osteoporosis are five times more likely to fracture in the subsequent year, and these fractures can be life-changing. Yet ...
Source: Amgen News Release - November 30, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Webcast Investor Call At ASH 2018
THOUSAND OAKS, Calif., Nov. 28, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition on Monday, Dec. 3, 2018, at 8 p.m. PT. David M. Reese, M.D., executive vice president of Research and Development at Amgen, together with other members of Amgen's management team and a clinical investigator, will participate to discuss data presented at ASH and the Company's oncology program, including the bispecific T Cell engager (BiTE®) immuno-oncology platform. Live audio of the investor call w...
Source: Amgen News Release - November 28, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present At the Piper Jaffray And Evercore ISI Healthcare Conferences
THOUSAND OAKS, Calif., Nov. 21, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Piper Jaffray Healthcare Conference at 8:30 a.m. ET on Tuesday, Nov. 27, 2018, in New York City and at the Evercore ISI Healthcare Conference at 11 a.m. ET on Wednesday, Nov. 28, 2018, in Boston. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at the conferences. Live audio of each presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of each webcast will also be available on Amgen's website for at least 90 days following the...
Source: Amgen News Release - November 21, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO ® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
First and Only EU Marketing Authorization Application to Include Presence of Minimal Residual Disease Application Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia THOUSAND OAKS, Calif., Nov. 16, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for BLINCYTO® (blinatumomab) monotherapy to include adult patients with Philadelphia chromosome negative CD19 ...
Source: Amgen News Release - November 16, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha ® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018
Additional Data Analyzing Treatment Patterns in the United States Shows Underutilization of LDL-C Lowering Treatments in At-Risk Patients and Need for Improved Patient Awareness of Treatment Goals THOUSAND OAKS, Calif., Nov. 12, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the final report of the Open-Label Study of Long-TERm Evaluation Against LDL-C (OSLER-1), demonstrating long-term treatment with Repatha® (evolocumab) was associated with robust and consistent reductions in low-density lipoprotein cholesterol (LDL-C), with no increase in overall rates of adverse events over time and no neutraliz...
Source: Amgen News Release - November 12, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Foundation Pledges $500,000 In Relief To Victims Of Ventura And Los Angeles County Wildfires
New Pledge is in Addition to $250,000 Contribution to Ventura County Community Foundation's Conejo Valley Victims Fund THOUSAND OAKS, Calif., Nov. 12, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Amgen Foundation has pledged $500,000 to support victims of the local wildfires in Ventura and Los Angeles Counties. The Amgen Foundation will select recipient non-profit organizations based on relief effort needs. In addition, the Amgen Foundation has committed $250,000 to the Ventura County Community Foundation's Conejo Valley Victims Fund to support the victims, families and organizations providin...
Source: Amgen News Release - November 12, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha ® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018
Additional Analyses of Real-World Data Will Explore Treatment Utilization and Understanding of Treatment Goals in Patients at High Risk for Cardiovascular Events THOUSAND OAKS, Calif., Nov. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of 10 scientific research abstracts, including the final report of the OSLER-1 study, evaluating the long-term safety and efficacy of Repatha® (evolocumab) in patients with hypercholesterolemia for up to five years. Additional abstracts to be presented include a sub-analysis of the Repatha cardiovascular outcomes study (FOURIER), investigating the...
Source: Amgen News Release - November 5, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease
Provention to Lead Phase 2b Stage of Development for Anti-IL-15 Antibody AMG 714 Amgen Will Invest $20 Million in Provention Equity Amgen Will be Responsible for Clinical Trial Supply and Manufacturing THOUSAND OAKS, Calif. and OLDWICK, N.J., Nov. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Provention Bio, Inc. (NASDAQ:PRVB), a clinical-stage biopharmaceutical company focused on immune-mediated diseases, today announced a licensing and co-development agreement for AMG 714, identified by Provention as PRV-015. AMG 714 is a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-fre...
Source: Amgen News Release - November 5, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present New Data Showcasing Extensive Portfolio And Exciting Early Oncology Pipeline At ASH 2018
First-in-Human Data Evaluating AMG 420 in Multiple Myeloma and AMG 330 in Acute Myeloid Leukemia Underscore Potential of BiTE® Immunotherapy Platform Across Hematologic Malignancies BLINCYTO® (blinatumomab) Long-Term Data Demonstrate Benefits of Achieving Complete MRD Response in Adult Patients With Acute Lymphoblastic Leukemia and Reinforce BiTE® Proof-of-Concept Data From Multiple Myeloma Research Foundation CoMMpass Trial of KYPROLIS® (carfilzomib) in Newly Diagnosed Multiple Myeloma Patients to be Presented at ASH THOUSAND OAKS, Calif., Nov. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today ann...
Source: Amgen News Release - November 1, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Foundation Deepens Commitment To Aspiring Scientists Worldwide By Expanding Amgen Scholars Program
Through a new $21 Million, Four-Year Investment, Amgen Scholars Program to Reach Additional 1,500 Undergraduates Nearly 4,000 Undergraduates From More Than 700 Colleges and Universities Have Participated to Date Alumni Pursuing Advanced Scientific Degrees and Careers Across the U.S. and Globe THOUSAND OAKS, Calif., Nov. 1, 2018 /PRNewswire/ -- The Amgen Foundation today announced the expansion of the Amgen Scholars Program, a hands-on research program that allows undergraduates to spend a summer at one of many of the world's premier research institutions. The new four-year, $21 million commitment brings the p...
Source: Amgen News Release - November 1, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Reports Third Quarter 2018 Financial Results
THOUSAND OAKS, Calif., Oct. 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2018. Key results include: Total revenues increased 2 percent versus the third quarter of 2017 to $5.9 billion. Product sales grew 1 percent globally. New and recently launched products including Repatha® (evolocumab), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab) showed double-digit growth. GAAP earnings per share (EPS) increased 4 percent to $2.86 driven by higher total revenues, a lower tax rate and lower weighted-average shares out...
Source: Amgen News Release - October 30, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces New FOURIER Analysis Showing Benefit With Repatha ® (Evolocumab) In High-Risk Patients With Established Cardiovascular Disease And Chronic Kidney Disease
Repatha Results in Consistent Reductions in LDL-C Levels and Cardiovascular Events in Patients Independent of Kidney Function Results Presented at American Society of Nephrology Kidney Week 2018 THOUSAND OAKS, Calif., Oct. 26, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha® (evolocumab) in patients with established cardiovascular disease by kidney function. In line with previous FOURIER subgroup analyses, these results further demonstrate Repatha's efficacy in reducing not only low-density lipoprotein chole...
Source: Amgen News Release - October 27, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Webcast Of 2018 Third Quarter Financial Results
THOUSAND OAKS, Calif., Oct. 26, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2018 financial results on Tuesday, Oct. 30, 2018, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors...
Source: Amgen News Release - October 26, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Makes Repatha ® (Evolocumab) Available In The US At A 60 Percent Reduced List Price
New Option Will Lower Out-of-Pocket Costs for America's Seniors at Risk for Heart Attacks and Strokes THOUSAND OAKS, Calif., Oct. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it is making Repatha® (evolocumab), an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, available at a reduced list price of $5,850 per year. This 60 percent reduction from the medicine's original list price will improve affordability by lowering patient copays, especially for Medicare patients. To view the Multimedia News Release, go to: https://www.multi...
Source: Amgen News Release - October 24, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

First Head-to-Head Trial of a TNF Inhibitor Versus Methotrexate Monotherapy in Psoriatic Arthritis Shows ENBREL ® (Etanercept) Monotherapy and Combination Therapy Both Superior to Methotrexate
Results From Head-To-Head Phase 3 SEAM-PsA Study Assessing ENBREL and Methotrexate Regimens in Patients With Psoriatic Arthritis Presented at 2018 ACR/ARHP Annual Meeting Additional Phase 3b Results Show Modified ENBREL Formulation Associated With Significantly Lower Mean Injection Site Pain Versus Prior Formulation Data Presentations Result of Continued Dedication to Evaluate Optimal Use of ENBREL THOUSAND OAKS, Calif., Oct. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that positive results from the Phase 3 SEAM-PsA study comparing the efficacy of Enbrel® (etanercept) monotherapy and ENBREL pl...
Source: Amgen News Release - October 24, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces 2018 Fourth Quarter Dividend
THOUSAND OAKS, Calif., Oct. 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the fourth quarter of 2018. The dividend will be paid on Dec. 7, 2018, to all stockholders of record as of the close of business on Nov. 16, 2018. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understa...
Source: Amgen News Release - October 23, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Invests £50 Million ($66 Million) In Oxford Nanopore Technologies
THOUSAND OAKS, Calif. and OXFORD, England, Oct. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Oxford Nanopore Technologies Ltd. today announced Amgen's equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology. Oxford Nanopore has developed and brought to market a proprietary sequencing technology that uses many nanopores (nano-scale holes made by proteins contained within a synthetic membrane) in combination with electronics to perform direct, real-time sequencing of DNA and RNA. The...
Source: Amgen News Release - October 18, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Launches AMGEVITA ™ (Biosimilar Adalimumab) In Markets Across Europe
First Inflammation Biosimilar From Amgen's Portfolio to Launch in Europe THOUSAND OAKS, Calif., Oct. 15, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC). AMGEVITA is authorized for the treatment of inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidenc...
Source: Amgen News Release - October 16, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves KYPROLIS ® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Approval of a More Convenient Once-Weekly Kd70 Regimen Based on Data From Phase 3 Head-to-Head A.R.R.O.W. Study Application Granted Priority Review Designation Application Reviewed and Approved Under FDA's Real-Time Oncology Review and Assessment Aid Pilot Programs THOUSAND OAKS, Calif., Oct. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to expand the Prescribing Information for KYPROLIS® (carfilzomib) to include a once-weekly dosing option in combination with dexamethasone (once-weekly...
Source: Amgen News Release - October 1, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

BLINCYTO ® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia
First Approved Oncology Treatment From Amgen Astellas Joint Venture BLINCYTO is the First-and-Only Approved CD19-Directed CD3 Bispecific T Cell Engager (BiTE®) Immunotherapy THOUSAND OAKS, Calif., Sept. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO® (blinatumomab) for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). BLINCYTO was developed in Japan by Amgen Astellas BioPharma K.K. (AABP), a joint venture between Amgen and Astellas Pharma Inc., a pharmaceuti...
Source: Amgen News Release - September 25, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Los Angeles County Announce Collaboration To Support Life Science Innovation Hub - BioLA
Amgen's David Piacquad to Join BioLA Board of Directors THOUSAND OAKS, Calif. and LOS ANGELES, Sept. 20, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and the County of Los Angeles today announced that Amgen has agreed to become a founding sponsor of BioLA, a newly formed organization focused on advancing a life science innovation hub in Los Angeles County. The innovation hub is designed to contribute to advancements in global health by strengthening the County's life sciences ecosystem and accelerating the pace of startup activity. BioLA will also focus on creating jobs, driving economic development and promoting the...
Source: Amgen News Release - September 20, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news